10216: A Phase I/II Study of AZD9291 (Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer

10166: A Phase 2 Study of Atezolizumab and Cobimetinib in PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

10268: Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) vs. Topotecan Alone in Patients with Relapsed Small Cell Lung Cancer (Exploratory cohort includes patients with extrapulmonary small cell cancers)

10402: BAY1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)

10445: Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Extensive-Stage Small Cell Lung Cancer

Non-Squamous

Advanced NSCLC

Non-small cell lung cancer (NSCLC)

NSCLC with presence or absence of known EGFR mutation

NSCLC with presence or absence of known KRAS mutation

Small cell lung cancer (SCLC)

SCLC

Lung Cancer

10012: A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer

10313: A Phase IB and Randomized Open-Label Phase II Study of M6620 in Combination with Carboplatin/Gemcitabine/Avosuamab in Patients with Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology

10327: A Phase I Trial of MLN0128 (TAK-228) and CB-839 HCl (talaglenastat) in Advanced NSCLC Patients

10216: A Phase III Study of AZD9291 (Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer

10166: A Phase 2 Study of Atezolizumab and Cobimetinib in PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

10512: A Limited trial; not open ETCTN-wide; Version Date: December 8, 2022